<DOC>
	<DOCNO>NCT00171704</DOCNO>
	<brief_summary>Estrogen know regulator bone lipid metabolism . Letrozole potent inhibitor estrogen synthesis . This study evaluate effect letrozole tamoxifen bone lipid metabolism postmenopausal woman resect , receptor positive early breast cancer .</brief_summary>
	<brief_title>A Study Evaluate Effect Letrozole Tamoxifen Bone Lipids Postmenopausal Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Inclusion Criteria Female Postmenopausal hormone status define : Patients menostasis ( amenorrhea ) &gt; 12 month history oophorectomy . Patients ≥ 55 year history hysterectomy continued/renewed menstruation cyclic hormone treatment . Patients 5054 year : Menopausal status determine basis folliclestimulating hormone ( FSH ) /luteinizing hormone ( LH ) value . Histologically confirm resect breast cancer eligible adjuvant endocrine therapy . As minimum , patient receptorpositive tumor , define either estrogen receptor ( ER ) and/or progesterone receptor ( PgR ) ≥ 10 fmol/mg cytosol protein ; ≥ 10 % tumor cell positive immunocytochemical evaluation . Adequate bone marrow function ( white blood cell count [ WBC ] &gt; 3.0 x 109 /L , platelet ≥ 100.0 x 109 /L , hemoglobin &gt; 10 g/dL ) . Documented evidence adequate renal function ( creatinine &lt; 180 µmol/L ) hepatic function ( bilirubin &lt; 30 µmol/L , alanine aminotransferase ( ALT ) &lt; 1.5 x upper normal limit laboratory ) . Life expectancy least 24 month time enrollment . Written voluntary inform consent prior initiation study procedure . Willingness undergo schedule test examination evaluation bone density bone metabolism , lipid profile addition standard assessment monitor breast cancer status . Exclusion Criteria Patients distant metastasis define criterion Danish Breast Cancer Cooperative Group ( DBCCOG ) . Preexisting bone disease ( e.g . osteomalacia , osteogenesis imperfecta , Paget 's disease ) . Patients receive bisphosphonates 3 month randomization . Chronic treatment drug know interfere bone metabolism , e.g . Anticonvulsants within past year . Corticosteroids dose great equivalent 5 mg/day prednisone two week past 6 month ( prior randomization ) . Any previous treatment sodium fluoride daily dos ≥ 5 mg/day period exceed 1 month . Anabolic steroids past 12 month . Long term use coumarin derivative heparin time randomization . Metabolic disease know interfere bone metabolism ( e.g. , Hyperparathyroidism , hypoparathyroidism , uncontrolled thyroid disease , Cushing 's disease , vitamin D deficiency , malabsorption syndrome , etc. ) . Treatment lipidlowering agent within 3 month prior randomization ( exclusion criterion apply patient randomize United Kingdom ) . Patients receive anticancer treatment . Previous neoadjuvant / adjuvant chemotherapy /or previous adjuvant endocrine therapy ( e.g. , antiestrogens , AIs ) . History previous concomitant malignancy within past 5 year adequately treat basal squamous cell carcinoma skin situ carcinoma cervix . Patients previous malignancy must disease free five year . Patients endometrial cancer and/or invasive breast cancer time medical history exclude . Patients invasive bilateral breast cancer exclude . Patients vaginal discharge/ vaginal bleeding evidence malignancy exclude . Any nonmalignant systemic disease ( cardiovascular , renal , hepatic , lung embolism , etc . ) would prevent prolonged followup .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>Bone Markers</keyword>
	<keyword>Serum lipid</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>